Sodium tetradecyl sulfate: Difference between revisions
Rabin Bista (talk | contribs) No edit summary |
Rabin Bista (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | {{DrugProjectFormSinglePage | ||
|authorTag=<!--Overview--> | |authorTag=<!--Overview-->{{RB}} | ||
|genericName=Sodium tetradecyl sulfate | |||
|aOrAn=a | |aOrAn=a | ||
|drugClass=sclerosing Agent | |||
|indicationType=treatment | |indicationType=treatment | ||
| | |indication=small uncomplicated varicose veins of the lower extremities | ||
|adverseReactions=<!--Black Box Warning--> | |adverseReactions=Local reactions consisting of pain, urticaria or ulceration, Allergic reactions | ||
<!--Black Box Warning--> | |||
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> | |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> | ||
<!--Adult Indications and Dosage--> | <!--Adult Indications and Dosage--> | ||
<!--FDA-Labeled Indications and Dosage (Adult)--> | <!--FDA-Labeled Indications and Dosage (Adult)--> | ||
|fdaLIADAdult====== | |fdaLIADAdult=====Indications==== | ||
* Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. | |||
==== | ====Dosage==== | ||
* Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if precipitated or discolored. | |||
Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL. | |||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
|offLabelAdultGuideSupport= | |||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
<!--Non–Guideline-Supported Use (Adult)--> | <!--Non–Guideline-Supported Use (Adult)--> | ||
|offLabelAdultNoGuideSupport====== | |offLabelAdultNoGuideSupport=* Esophageal varices<ref name="pmid9099596">{{cite journal| author=Iwase H, Kusugami K| title=Symposium on endoscopic hemostasis in gastric diseases. 2. Choice of endoscopic therapy for esophagogastric varices: aiming for safer and more effective therapy. | journal=Intern Med | year= 1997 | volume= 36 | issue= 2 | pages= 128-9 | pmid=9099596 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9099596 }} </ref> | ||
* Hemangioma<ref name="pmid3343573">{{cite journal| author=Anavi Y, Har-El G, Mintz S| title=The treatment of facial haemangioma by percutaneous injections of sodium tetradecyl sulfate. | journal=J Laryngol Otol | year= 1988 | volume= 102 | issue= 1 | pages= 87-90 | pmid=3343573 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3343573 }} </ref><ref name="pmid3823245">{{cite journal| author=Woods JE| title=Extended use of sodium tetradecyl sulfate in treatment of hemangiomas and other related conditions. | journal=Plast Reconstr Surg | year= 1987 | volume= 79 | issue= 4 | pages= 542-9 | pmid=3823245 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3823245 }} </ref> | |||
* | |fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients. | ||
===== | |||
< | |||
< | |||
| | |||
: | |||
===== | |||
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients. | |||
<!--Off-Label Use and Dosage (Pediatric)--> | <!--Off-Label Use and Dosage (Pediatric)--> | ||
<!--Guideline-Supported Use (Pediatric)--> | <!--Guideline-Supported Use (Pediatric)--> | ||
|offLabelPedGuideSupport= | |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
<!--Non–Guideline-Supported Use (Pediatric)--> | <!--Non–Guideline-Supported Use (Pediatric)--> | ||
|offLabelPedNoGuideSupport= | |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
<!--Contraindications--> | <!--Contraindications--> |
Revision as of 16:02, 19 February 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Sodium tetradecyl sulfate is a sclerosing Agent that is FDA approved for the treatment of small uncomplicated varicose veins of the lower extremities. Common adverse reactions include Local reactions consisting of pain, urticaria or ulceration, Allergic reactions.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
- Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks.
Dosage
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if precipitated or discolored.
Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Sodium tetradecyl sulfate in adult patients.
Non–Guideline-Supported Use
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Sodium tetradecyl sulfate in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Sodium tetradecyl sulfate in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Sodium tetradecyl sulfate in pediatric patients.
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Sodium tetradecyl sulfate in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Sodium tetradecyl sulfate in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sodium tetradecyl sulfate in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Sodium tetradecyl sulfate during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to specific gender populations.
Race
There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Sodium tetradecyl sulfate in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Sodium tetradecyl sulfate in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Sodium tetradecyl sulfate in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Sodium tetradecyl sulfate in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Sodium tetradecyl sulfate in the drug label.
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Sodium tetradecyl sulfate in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Sodium tetradecyl sulfate in the drug label.
Pharmacology
There is limited information regarding Sodium tetradecyl sulfate Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Sodium tetradecyl sulfate in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Sodium tetradecyl sulfate in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Sodium tetradecyl sulfate in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Sodium tetradecyl sulfate in the drug label.
How Supplied
Storage
There is limited information regarding Sodium tetradecyl sulfate Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Sodium tetradecyl sulfate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Sodium tetradecyl sulfate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Sodium tetradecyl sulfate in the drug label.
Precautions with Alcohol
- Alcohol-Sodium tetradecyl sulfate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- ®[4]
Look-Alike Drug Names
- A® — B®[5]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Iwase H, Kusugami K (1997). "Symposium on endoscopic hemostasis in gastric diseases. 2. Choice of endoscopic therapy for esophagogastric varices: aiming for safer and more effective therapy". Intern Med. 36 (2): 128–9. PMID 9099596.
- ↑ Anavi Y, Har-El G, Mintz S (1988). "The treatment of facial haemangioma by percutaneous injections of sodium tetradecyl sulfate". J Laryngol Otol. 102 (1): 87–90. PMID 3343573.
- ↑ Woods JE (1987). "Extended use of sodium tetradecyl sulfate in treatment of hemangiomas and other related conditions". Plast Reconstr Surg. 79 (4): 542–9. PMID 3823245.
- ↑ Empty citation (help)
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Sodium tetradecyl sulfate |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}} |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Sodium tetradecyl sulfate |Label Name=Sodium tetradecyl sulfate11.png
}}
{{#subobject:
|Label Page=Sodium tetradecyl sulfate |Label Name=Sodium tetradecyl sulfate11.png
}}